Lixte Biotechnology Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Lixte Biotechnology Holdings, Inc. reported a significantly wider net loss in 2025, driven by increased administrative costs and digital asset losses, while strategically acquiring a proton therapy system and navigating clinical trial developments.
NASDAQ
10-K: Lixte Biotechnology Holdings Reports on Clinical Trials and Financial Results in Annual 10-K Filing
Lixte Biotechnology Holdings provides an update on its clinical-stage biopharmaceutical activities and financial standing in its annual report, highlighting ongoing trials and the need for future capital.
NASDAQ
Lixte Biotechnology Holdings, a clinical-stage biopharmaceutical company, released its 2023 annual report, detailing ongoing clinical trials and financial status.